Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients

Laryngoscope

Volumn 122, Issue 6, 2012, Pages 1392-1396

  Eiamprapai, Peem ^a,b   Yamamoto, Norio ^a   Hiraumi, Harukazu ^a   Ogino Nishimura, Eriko ^a   Kitamura, Morimasa ^a   Hirano, Shigeru ^a   Ito, Juichi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MAHASARAKHAM UNIVERSITY   (Thailand)

Author keywords

cisplatin; Distortion product otoacoustic emissions; head and neck cancer; ototoxicity

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISTORTION PRODUCT OTOACOUSTIC EMISSION; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENETIC DIFFERENCE; HEAD AND NECK CANCER; HUMAN; INCIDENCE; JAPANESE; MALE; OTOTOXICITY; PATIENT REFERRAL; PRIORITY JOURNAL; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL;

EID: 85027927328     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23336     Document Type: Article

References (26)

1. Budach W, Hehr T, Budach V, Belka C, Dietz K,. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006; 6: 28.
2. Rybak LP, Mukherjea D, Jajoo S, Ramkumar V,. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 2009; 219: 177-186.
3. Komune S, Asakuma S, Snow JB,. Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum. Otolaryngol Head Neck Surg 1981; 89: 275-282.
4. Ress BD, Sridhar KS, Balkany TJ, Waxman GM, Stagner BB, Lonsbury-Martin BL,. Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Third place-Resident Clinical Science Award 1998. Otolaryngol Head Neck Surg 1999; 121: 693-701.
5. Oldenburg J, Fossa SD, Ikdahl T,. Genetic variants associated with cisplatin-induced ototoxicity. Pharmacogenomics 2008; 9: 1521-1530.
6. Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 2007; 81: 427-437.
7. Beattie RC, Kenworthy OT, Luna CA,. Immediate and short-term reliability of distortion-product otoacoustic emissions. Int J Audiol 2003; 42: 348-354.
8. Knight KR, Kraemer DF, Winter C, Neuwelt EA,. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007; 25: 1190-1195.
9. Schaefer SD, Post JD, Close LG, Wright CG,. Ototoxicity of low- and moderate-dose cisplatin. Cancer 1985; 56: 1934-1939.
10. Vermorken JB, Kapteijn TS, Hart AA, Pinedo HM,. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983; 19: 53-58.
11. Reavis KM, Phillips DS, Fausti SA, et al. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss. Ear Hear 2008; 29: 875-893.
12. Strumberg D, Brugge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13: 229-236.
13. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77: 1355-1362.
14. Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G,. Evoked otoacoustic emissions-an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 2001; 59: 47-57.
15. Biro K, Noszek L, Prekopp P, et al. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology 2006; 70: 177-184.
16. Nelson HH, Wiencke JK, Christiani DC, et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995; 16: 1243-1245.
17. Barahmani N, Carpentieri S, Li XN, et al. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro Oncol 2009; 11: 292-300.
18. Riedemann L, Lanvers C, Deuster D, et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 2008; 8: 23-28.
19. Ross CJ, Katzov-Eckert H, Dube MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41: 1345-1349.
20. Lee JE, Nakagawa T, Kim TS, et al. Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment. Acta Otolaryngol 2004; 124: 1131-1135.
21. Kikkawa YS, Nakagawa T, Horie RT, Ito J,. Hydrogen protects auditory hair cells from free radicals. Neuroreport 2009; 20: 689-694.
22. Choe WT, Chinosornvatana N, Chang KW,. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol 2004; 25: 910-915.
23. Campbell KC, Meech RP, Rybak LP, Hughes LF,. The effect of D-methionine on cochlear oxidative state with and without cisplatin administration: mechanisms of otoprotection. J Am Acad Audiol 2003; 14: 144-156.
24. Minami SB, Sha SH, Schacht J,. Antioxidant protection in a new animal model of cisplatin-induced ototoxicity. Hear Res 2004; 198: 137-143.
25. Wang J, Ladrech S, Pujol R, Brabet P, Van De Water TR, Puel JL,. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res 2004; 64: 9217-9224.
26. Cooper J, Kiehart D,. Septins may form a ubiquitous family of cytoskeletal filaments. J Cell Biol 1996; 134: 1345-1348.